H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Freeline Therapeutics to $2 from $15 and keeps a Buy rating on the shares post the Q4 results. The analyst removed FLT190 and the assumed platform value from the firm’s estimates, as well as moderated its assumed probability of success on FLT201. With FLT190 paused, all eyes are on FLT201 in 2023, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on FRLN:
- Freeline downgraded to Hold from Buy at Stifel
- Freeline, Forcefield sign exclusive patent, know-how license agreement
- Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update
- Freeline reports FY22 EPS ($1.50), consensus ($1.99)
- Freeline Therapeutics Holdings Plc Sponsored ADR (FRLN) Q4 Earnings Cheat Sheet
